Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 According to trial design presented at 19th World Conference on Lung Cancer ,as of 5/4/18, the trial is open at 8 centers with 14 patients enrolled.
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
- 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, as of 2/13/18, the trial has been opened at 4 centers and 8 patients have been enrolled.